Agios Pharmaceuticals Inc. (NASDAQ:AGIO)’s share price was up 4.3% during mid-day trading on Tuesday . The company traded as high as $49.96 and last traded at $49.62, with a volume of 554,081 shares trading hands. The stock had previously closed at $47.57.

A number of equities analysts have issued reports on AGIO shares. Canaccord Genuity reiterated a “buy” rating and set a $90.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, September 8th. Vetr cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $68.42 target price on the stock. in a research report on Tuesday, June 7th. Cowen and Company reissued a “buy” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, May 24th. Credit Suisse Group AG reissued a “buy” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, July 12th. Finally, Goldman Sachs Group Inc. reissued a “hold” rating and set a $46.00 target price on shares of Agios Pharmaceuticals in a research report on Monday, June 13th. Seven research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $63.44.

The company’s 50-day moving average price is $41.70 and its 200-day moving average price is $45.03. The stock’s market capitalization is $1.90 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/agios-pharmaceuticals-inc-agio-trading-up-4-3.html

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.47) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by $0.99. Agios Pharmaceuticals had a negative return on equity of 47.69% and a negative net margin of 320.33%. The company earned $6.98 million during the quarter, compared to analysts’ expectations of $39.62 million. During the same quarter in the prior year, the business posted ($0.85) EPS. The company’s revenue for the quarter was down 47.2% compared to the same quarter last year. Equities research analysts anticipate that Agios Pharmaceuticals Inc. will post ($5.04) earnings per share for the current fiscal year.

In related news, Director Lewis Clayton Jr. Cantley sold 2,504 shares of the firm’s stock in a transaction that occurred on Tuesday, June 28th. The shares were sold at an average price of $41.88, for a total value of $104,867.52. Following the sale, the director now owns 125,921 shares in the company, valued at $5,273,571.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 10.55% of the stock is currently owned by corporate insiders.

Large investors have recently modified their holdings of the company. Wellington Management Group LLP boosted its stake in shares of Agios Pharmaceuticals by 0.6% in the first quarter. Wellington Management Group LLP now owns 5,299,078 shares of the biopharmaceutical company’s stock valued at $215,141,000 after buying an additional 31,611 shares in the last quarter. BB Biotech AG boosted its stake in shares of Agios Pharmaceuticals by 9.4% in the second quarter. BB Biotech AG now owns 2,363,321 shares of the biopharmaceutical company’s stock valued at $99,011,000 after buying an additional 203,400 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Agios Pharmaceuticals by 10.1% in the second quarter. Vanguard Group Inc. now owns 2,105,591 shares of the biopharmaceutical company’s stock valued at $88,214,000 after buying an additional 192,852 shares in the last quarter. Flagship Ventures Fund 2007 L.P. bought a new stake in shares of Agios Pharmaceuticals during the first quarter valued at about $78,373,000. Finally, Capital International Investors boosted its stake in shares of Agios Pharmaceuticals by 11.4% in the second quarter. Capital International Investors now owns 1,501,037 shares of the biopharmaceutical company’s stock valued at $62,886,000 after buying an additional 153,464 shares in the last quarter. Institutional investors own 93.20% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

5 Day Chart for NASDAQ:AGIO

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.